
Alpha Profiles · Company Profile
Spero Therapeutics, Inc.
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare…
https://registry.alpha.ac/companies/spero-therapeutics-inc
- Entity
- Public listing published
- Primary listing
- NASDAQ: SPRO
- Verification
- Partially verified
- Last reviewed
- 2026-09-13T04:46:54.283359+00:00
Overview
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephri
Source record
Alpha canonical company public projection
Supports Company identity, Published leadership, Entity status boundary
Reviewed 2026-09-13T04:46:54.283359+00:00
